The rise of bispecific antibody-drug conjugates (ADCs) marks a promising new frontier in urothelial carcinoma (UC) treatment. As several ADCs are advancing through clinical trials, staying up to date with the latest evidence is critical.Tune in to this Clinical Mic Drop as we interview an expert oncologist about the latest clinical trial data on emerging bispecific ADCs and the potential impact of these novel therapies on the treatment landscape for patients with UC.Through the components of this educational activity, you have the opportunity to earn 2.25 CE credits in total. You can earn 0.25 CE credits by participating in the Clinical Mic Drop. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn up to 2.0 CE credits. If you decide not to engage in completion of the entirety of these articles, you can still claim partial credit based on your level of participation.Total Possible Credits: 2.25 CECredits from PRIME Booster Quiz: 0.25 CECredits from SynopsiMedEd Related Evidence: 2.0 CE
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 360 Park Avenue South
Pricing
99% of listed courses are free
298 of a sample of 300 are free · 416 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Pediatrics
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Interventional Radiology
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Musculoskeletal Oncology
- Nephrology
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Pediatric Neurology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.25 credits
- Commercial Support
-
ReleasedAug 21, 2026
-
Last day to claim creditAug 21, 2027 10 months left
-
PRIME Education, Inc. (PRIME®) Unlocking Expertise in Bispecific ADCs: Therapeutic Rationale and Emerging Data in NSCLC, TNBC, and Urothelial Carcinoma
-
PRIME Education, Inc. (PRIME®) Novel Advancements in TNBC: Bispecific ADCs and Emerging Clinical Trial Data
-
PRIME Education, Inc. (PRIME®) Treating Advanced Disease With Bispecific ADCs: Mechanisms of Action and Therapeutic Rationale for Bispecific ADCs in Solid Tumors
